| Dr Robert Marvin Kent, MD | |
|
1203 S Locust St, Glenwood, IA 51534-1872 | |
| (712) 527-3699 | |
| Not Available |
| Full Name | Dr Robert Marvin Kent |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 1203 S Locust St, Glenwood, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043434525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD-38295 (Iowa) | Secondary |
| 207Q00000X | Family Medicine | 5484 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Angels Care Home Health Of Iowa | Council bluffs, IA | Home health agency |
| Chi Health Bergan Mercy | Omaha, NE | Hospital |
| Chi Health Mercy Council Bluffs | Council bluffs, IA | Hospital |
| Methodist Jennie Edmundson | Council bluffs, IA | Hospital |
| Glen Haven Home | Glenwood, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alegent Creighton Clinic | 1951210418 | 827 |
News Archive
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles - ULB Cancer Research Center, U-CRC - show the causal link between aneuploidy and cancer.
Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598811069 PECOS PAC ID: 1951210418 Enrollment ID: O20040116000817 |
News Archive
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles - ULB Cancer Research Center, U-CRC - show the causal link between aneuploidy and cancer.
Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Marvin Kent, MD 1203 S Locust St, Glenwood, IA 51534-1872 Ph: (712) 527-3699 | Dr Robert Marvin Kent, MD 1203 S Locust St, Glenwood, IA 51534-1872 Ph: (712) 527-3699 |
News Archive
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles - ULB Cancer Research Center, U-CRC - show the causal link between aneuploidy and cancer.
Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
Dr. Dominic Shiu, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 711 S Vine St, Glenwood, IA 51534 Phone: 712-520-2210 Fax: 712-525-1459 | |
Dr. Ronald D Silvius, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 Ebaugh St, Glenwood, IA 51534 Phone: 712-527-5204 Fax: 712-527-9346 | |
Mathew J Lukey, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 Ebaugh St, Glenwood, IA 51534 Phone: 712-527-5204 Fax: 712-527-9346 | |
Dr. John Joseph Heffron, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 S Vine St, Glenwood, IA 51534 Phone: 712-527-4811 Fax: 712-525-1670 | |
Mr. Michael Dale Schmiesing, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 Ebaugh St, Glenwood, IA 51534 Phone: 712-527-5204 Fax: 712-527-9346 | |
Dr. Robert Kenneth Fryzek, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: Po Box 69, Glenwood, IA 51534 Phone: 712-527-9135 Fax: 712-527-5679 |